Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Long-term Objective A  

$1,168,146.00
Fiscal Year: 2009

Yellow dot: Objective has some degree of funding, but less than the recommended amount.4LA. Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.

Download 2009 Question 4: Long-term Objective A projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Clinical Trials Network Staff Member Autism Speaks (AS)
Intransal oxytocin in the treatment of autism Anagnostou, Athanasius Mount Sinai School of Medicine
Oxytocin vs. placebo on response inhibition and face processing in autism Anagnostou, Athanasius Mount Sinai School of Medicine
The effects of oxytocin on complex social cognition in autism spectrum disorders Bartz, Jennifer Mount Sinai School of Medicine
ACE Center: Understanding repetitive behavior in autism McCracken, James University of California, Los Angeles
ACE Center: Understanding repetitive behavior in autism (supplement) McCracken, James University of California, Los Angeles
ACE Center: The pharmacogenetics of treatment for insistence on sameness in autism Owley, Thomas University of Illinois at Chicago
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Stein, Peter University of Medicine & Dentistry of New Jersey
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Johnson, William University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Developing treatment, treatment validation, and treatment scope in the setting of an autism clinical trial Novotny, Sherie University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014.

IACC Recommended Budget: $22,200,000 over 5 years
4.8
$1,380,376
12 projects

4.L.A
$1,168,146
10 projects

4.L.A
$1,924,932
11 projects

4.L.A
$1,527,858
12 projects

4.L.A
$3,713,783
14 projects

$9,715,095
4.L.A. Funding: The recommended budget was partially met.

Progress: 10-14 studies have been funded, which is more than the minimum recommended, and momentum within the pre-clinical phases of this objective is currently building. It should be noted, however, in that many of these studies are small trials or pilot studies. 

Remaining Gaps, Needs, and Opportunities: Though there is little evidence that CNS drug development in animals will translate to humans, either in terms of toxicity or efficacy, there is still a need for investment in well-established animal model studies to identify promising molecular, cellular, or systems targets before mounting randomized clinical trials in humans. However, existing drugs for other indications may be adapted to ASD without extensive pre-clinical work, and there is also evidence for proof of concept studies for ASD (particularly those addressing core symptoms). It is also critically important to develop appropriate outcome measures for use in trials.